1 Global Angio Suites (DSA) Market Outlook
The global Angio Suites (DSA) market is projected to exhibit substantial growth in the coming years, with a CAGR of 5.19% from 2024 to 2033, reaching a total market size of $9370.2 million USD in 2024. Angio Suites (DSA), or Digital Subtraction Angiography, is a sophisticated medical imaging technology that processes angiography images digitally to eliminate unnecessary tissue images, retaining only the vascular structures. This technology is characterized by its high-resolution and clear imaging capabilities, providing real-time three-dimensional views of blood vessels. DSA is crucial for diagnosing and treating a wide range of vascular diseases, including coronary heart disease, arrhythmia, valvular disease, and congenital heart conditions. It has revolutionized interventional therapies, offering detailed visualization that aids in accurate diagnosis, effective treatment planning, and improved patient outcomes. The application of DSA in interventional procedures has opened new avenues for treating cardiovascular diseases, making it an indispensable tool in modern healthcare.
Figure Global Angio Suites (DSA) Market Size and Growth Rate (2024-2033)
2 Angio Suites (DSA) Market Growth Drivers and Constraints
The growth of the Angio Suites (DSA) market is propelled by several key drivers. The most significant is the increasing prevalence of cardiovascular diseases globally. Conditions such as coronary heart disease, stroke, and heart failure are on the rise, driving the demand for advanced diagnostic and treatment tools like DSA. Governments worldwide are also supporting the development of medical device industries, recognizing their importance in improving healthcare outcomes. For instance, China’s “Made in China 2025” plan includes high-performance medical devices as a strategic focus, aiming to enhance innovation and industrialization in this sector. Additionally, the integration of new technologies such as artificial intelligence and big data into medical imaging is creating new opportunities for the industry, enhancing diagnostic accuracy and efficiency.
However, the market also faces certain limitations. One major challenge is the strict regulatory environment for medical devices. Products must comply with stringent regulations and obtain approvals such as FDA registration in the United States or CE certification in Europe. These processes can be time-consuming and costly, posing barriers to market entry. Rising labor costs, exacerbated by the COVID-19 pandemic, have also increased operational expenses for manufacturers. For example, Germany experienced a significant rise in labor costs in 2020, impacting the profitability of medical device producers. These factors, combined with the high technical barriers and the need for specialized personnel, can slow down market expansion, especially in developing countries.
3 Angio Suites (DSA) Market Innovations and M&A Activities
The Angio Suites (DSA) market is characterized by continuous technological innovation and strategic corporate activities. Companies are leveraging advancements in imaging technology, artificial intelligence, and data analytics to enhance their products. For instance, Siemens Healthineers’ acquisition of Varian Medical Systems in 2021 aims to create a comprehensive ecosystem for cancer diagnosis and treatment, integrating DSA technology with other medical solutions. This move not only strengthens Siemens’ market position but also opens new opportunities in precision medicine.
Corporate mergers and acquisitions are also shaping the industry landscape. In recent years, several major players have engaged in strategic partnerships and acquisitions to expand their portfolios and enhance their market presence. For example, Canon Medical Systems’ strategic changes to reinforce its global HIT division highlight the importance of integrating healthcare information technology with imaging solutions. These initiatives are aimed at improving patient outcomes and streamlining healthcare delivery.
Moreover, the development of new technologies such as cloud computing and AI is driving the evolution of DSA systems. AI-powered imaging solutions can automate the analysis of medical images, reducing diagnostic errors and improving efficiency. These innovations are not only enhancing the capabilities of DSA systems but also creating new business models and opportunities for market players.
In conclusion, the Angio Suites (DSA) market is poised for continued growth, driven by technological advancements, strategic corporate activities, and increasing demand for advanced medical imaging. However, regulatory challenges and rising operational costs must be addressed to ensure sustainable development. As the industry progresses, the integration of AI and other emerging technologies will play a crucial role in shaping the future of DSA and its applications in healthcare.
4 Global Angio Suites (DSA) Market Analysis by Type
In 2024, the global Angio Suites (DSA) market is segmented into two primary types: Biplane Angio Suites and Single Plane Angio Suites. According to the market forecast, the sales and market share for each type are as follows:
Biplane Angio Suites:
Sales (Units): In 2024, the sales volume for Biplane Angio Suites is expected to reach approximately 5,001 units.
Market Share: Biplane Angio Suites are projected to hold a market share of 57.42% in 2024. This type is favored for its versatility and ability to perform a wide range of complex procedures, making it a preferred choice for advanced diagnostic and interventional applications.
Single Plane Angio Suites:
Sales (Units): The sales volume for Single Plane Angio Suites is expected to be around 3,709 units in 2024.
Market Share: Single Plane Angio Suites are expected to hold a market share of 42.58% in 2024. These systems are more cost-effective and are suitable for a broader range of applications, making them attractive for a wider market segment.
Overall, the market is driven by the increasing demand for advanced imaging solutions in the diagnosis and treatment of cardiovascular and other vascular diseases. Biplane systems continue to dominate due to their superior capabilities, while single-plane systems offer a more accessible option for a broader range of healthcare facilities.
Table Global Angio Suites (DSA) Sales and Share by Type in 2024
Type | Sales in 2024 (Units) | Market Share in 2024 (%) |
|---|---|---|
Biplane Angio Suites | 5001 | 57.42% |
Single Plane Angio Suites | 3709 | 42.58% |
5 Global Angio Suites (DSA) Market Analysis by Application
In 2024, the Angio Suites (DSA) market is projected to reach a value of $9370.2 million, with significant growth driven by the increasing prevalence of cardiovascular diseases and the rising demand for minimally invasive procedures. The market is segmented by application into three main areas: Hospitals, Clinics, and Other Applications. Below are the specific sales (units) and market share forecasts for each application in 2024:
Hospitals:
Sales (Units): Hospitals are expected to account for the largest number of Angio Suites sold in 2024, with an estimated sales volume of 5,981 units.
Market Share: This segment is projected to hold the largest market share at 68.67%, driven by the high demand for advanced imaging and interventional procedures in hospital settings.
Clinics:
Sales (Units): Clinics are expected to have a sales volume of 2,471 units in 2024.
Market Share: This segment is projected to hold a market share of 28.37%, driven by the growing number of specialized clinics offering advanced diagnostic services.
Other Applications:
Sales (Units): Other applications, including research centers and specialized facilities, are expected to account for 258 units.
Market Share: This segment is projected to hold a market share of 2.96%, driven by niche applications and emerging markets.
Overall, the Angio Suites (DSA) market in 2024 is poised for robust growth, with hospitals continuing to dominate due to their critical role in providing advanced diagnostic and interventional services. The market is expected to grow at a CAGR of 5.8% from 2024 to 2031, driven by technological advancements and increasing healthcare investments.
Table Global Angio Sales Market Size and Share by Application in 2024
Application | Sales in 2024 (Units) | Market Share in 2024 (%) |
|---|---|---|
Hospitals | 5981 | 68.67% |
Clinics | 2471 | 28.37% |
Others | 258 | 2.96% |
6 Global Angio Suites (DSA) Market Analysis by Region
In 2024, the Angio Suites (DSA) market is projected to experience significant growth across various regions, driven by increasing healthcare investments and the prevalence of cardiovascular diseases. The global market size is estimated to reach $2.06 billion, with a CAGR of 5.8% from 2024 to 2031. Below are the specific sales (units) and market share forecasts for each region in 2024:
North America:
Sales (Units): North America is expected to remain the largest market, with sales projected to reach 2,794 units.
Market Share: This region is anticipated to hold the largest market share at 32.08%, driven by advanced healthcare infrastructure and significant investments in medical technology.
Europe:
Sales (Units): Europe is projected to have sales of 2,614 units.
Market Share: This region is expected to hold a market share of 30.01%, supported by well-established healthcare systems and increasing investments in medical facilities.
Asia-Pacific:
Sales (Units): The Asia-Pacific region is projected to be the fastest-growing region, with sales reaching 2,819 units.
Market Share: This region is expected to hold a market share of 32.37%, driven by rapid economic development and increasing healthcare spending in emerging economies like China and India.
Latin America, Middle East, and Africa:
Sales (Units): These regions collectively are expected to account for 227 units.
Market Share: Together, they are projected to hold a market share of 2.61%, driven by increasing investments in healthcare infrastructure and growing awareness of cardiovascular health.
Overall, the Angio Suites (DSA) market in 2024 is poised for robust growth, with North America and Europe maintaining significant market shares, while the Asia-Pacific region is expected to see the most rapid expansion.
Figure Global Angio Suites (DSA) Market Share by Region in 2024
7 Top 3 Companies of Global Angio Suites (DSA) Market
7.1 Siemens Healthcare
Company Introduction and Business Overview:
Siemens Healthineers is a leading global medical technology company, offering a comprehensive portfolio of imaging, laboratory diagnostics, and digital health solutions. Established in 1847, the company has a strong presence in over 190 countries, with a focus on innovation and technological advancement. Siemens Healthineers is committed to improving patient outcomes through advanced medical technologies and is recognized for its robust R&D capabilities and strategic acquisitions.
Products Offered:
Siemens Healthineers offers a range of Angio Suites, including the ARTIS icono, which is designed for interventional radiology and cardiology procedures. The ARTIS icono system provides advanced imaging capabilities, supporting minimally invasive procedures with high-resolution images and real-time diagnostics. Additionally, Siemens’ portfolio includes biplane and single-plane angiography systems, which cater to various clinical needs and applications.
Sales Revenue in the Latest Year:
In the latest year, Siemens Healthineers reported significant revenue from its Angio Suites segment. The company’s total revenue from Angio Suites was approximately $2.35 billion, reflecting its strong market position and continuous investment in R&D and product development. This revenue is bolstered by the company’s global presence and its focus on providing comprehensive solutions for cardiovascular and interventional procedures.
7.2 Philips Healthcare
Company Introduction and Business Overview:
Philips Healthcare is a global leader in health technology, offering a wide range of solutions for diagnosis, treatment, and patient monitoring. Established in 1891, Philips operates in over 100 countries, with a focus on improving patient outcomes through advanced medical technologies. The company is recognized for its innovative approach and commitment to sustainability and patient-centric care.
Products Offered:
Philips Healthcare offers a range of Angio Suites, including the Azurion 7 B20/15 system, which is designed for interventional neuroradiology and cardiology procedures. The Azurion system provides advanced imaging capabilities, supporting minimally invasive procedures with high-resolution images and real-time diagnostics. Philips’ portfolio also includes single-plane and biplane angiography systems, which cater to various clinical needs and applications.
Sales Revenue in the Latest Year:
In the latest year, Philips Healthcare reported significant revenue from its Angio Suites segment. The company’s total revenue from Angio Suites was approximately $2.08 billion, reflecting its strong market position and continuous investment in R&D and product development. This revenue is bolstered by Philips’ global presence and its focus on providing comprehensive solutions for cardiovascular and interventional procedures.
7.3 GE Healthcare
Company Introduction and Business Overview:
GE Healthcare is a subsidiary of General Electric, specializing in medical imaging, diagnostics, and healthcare technologies. Established in 1892, GE Healthcare operates globally, with a focus on developing advanced medical devices and solutions that improve patient care. The company is known for its innovative approach and strategic partnerships, which drive technological advancements in the healthcare sector.
Products Offered:
GE Healthcare offers a variety of Angio Suites, including the Discovery™ IGS 7 system, which is designed for hybrid operating rooms. This system provides high-quality imaging and advanced applications, supporting a wide range of endovascular and interventional procedures. GE Healthcare’s portfolio also includes single-plane and biplane angiography systems, which are tailored to meet the diverse needs of hospitals and clinics.
Sales Revenue in the Latest Year:
In the latest year, GE Healthcare reported substantial revenue from its Angio Suites segment. The company’s total revenue from Angio Suites was approximately $1.75 billion, reflecting its strong market position and continuous innovation in medical imaging technologies. This revenue is supported by GE Healthcare’s global presence and its focus on providing advanced solutions for cardiovascular and interventional procedures.